ACB AURORA CANNABIS INC IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1683541 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2022-06-30 (FY2022), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.8%
TTM net income YoY-148.2%
TTM EPS YoY-94.9%
Revenue 3-yr CAGR-3.4%
Net income 3-yr CAGR—
Margins
Gross margin9.6%
Operating margin-104.6%
Net margin-776.0%
FCF margin-64.4%
EBITDA margin-82.6%
Returns
ROE-127.3%
ROA-93.1%
ROIC (approx.)-19.9%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets38.9%
Debt / equity0.00x
Current ratio5.69x
Interest coverage-3.22x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-87.1%
Payout ratio—
Capex / revenue14.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-03-31 | FY2024*2024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | 343.29M | 269.64M |
| Gross profit | 187.61M | 131.73M |
| R&D expense | 3.68M | 3.57M |
| SG&A expense | 97.26M | 91.33M |
| Operating income | 4.95M | -45.10M |
| Interest expense | 8.42M | 13.80M |
| Pretax income | 20.38M | -57.64M |
| Income tax | 4.62M | -554,000 |
| Net income | 1.59M | -69.33M |
| EBITDA | 14.03M | -33.12M |
| EPS (basic) | 0.04 | -1.52 |
| EPS (diluted) | 0.04 | -1.52 |
| Weighted avg. shares (diluted) | 55.62M | 43.22M |
| Balance sheet | ||
| Cash & equivalents | 137.92M | 136.09M |
| Short-term investments | 554,000 | 4.04M |
| Receivables | 42.47M | 45.41M |
| Inventory | 187.93M | 143.60M |
| Current assets | 478.33M | 426.61M |
| PP&E, netmay include right-of-use assets (IFRS) | 268.11M | 294.32M |
| Goodwill | 43.87M | 43.18M |
| Intangibles | 45.16M | 40.85M |
| Total assets | 852.67M | 838.67M |
| Current liabilities | 110.86M | 124.62M |
| Short-term debt | 2.30M | 52.36M |
| Long-term debt | 40.19M | 4.90M |
| Total debt | 42.49M | 57.26M |
| Total liabilities | 244.07M | 236.80M |
| Shareholders' equity | 567.17M | 559.77M |
| Net debt | -95.43M | -78.84M |
| Cash flow statement | ||
| Operating cash flow | 16.00M | -68.51M |
| Investing cash flow | -14.33M | -3.36M |
| Financing cash flow | -116,000 | -47.92M |
| Depreciation & amortization | 9.08M | 11.98M |
| Stock-based compensation | 11.52M | 12.72M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.